PPARG and Sepsis: Numerous in vivo and in vitro studies have shown that administration of PPARγ agonists can suppress the inflammatory responses associated with sepsis [9], acute lung injury [10], and inflammation [11], increasing the host’s ability to kill and clear pathogenic bacteria and improving prognosis.